263 related articles for article (PubMed ID: 20713171)
1. Impact of CRF01_AE-specific polymorphic mutations G335D and A371V in the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors.
Tanuma J; Hachiya A; Ishigaki K; Gatanaga H; Lien TT; Hien ND; Kinh NV; Kaku M; Oka S
Microbes Infect; 2010 Dec; 12(14-15):1170-7. PubMed ID: 20713171
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.
Hachiya A; Shimane K; Sarafianos SG; Kodama EN; Sakagami Y; Negishi F; Koizumi H; Gatanaga H; Matsuoka M; Takiguchi M; Oka S
Antiviral Res; 2009 Jun; 82(3):115-21. PubMed ID: 19428602
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
Liu J; Yue J; Wu S; Yan Y
Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.
Lengruber RB; Delviks-Frankenberry KA; Nikolenko GN; Baumann J; Santos AF; Pathak VK; Soares MA
J Antimicrob Chemother; 2011 Apr; 66(4):702-8. PubMed ID: 21393163
[TBL] [Abstract][Full Text] [Related]
5. The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains.
Li S; Ouyang J; Zhao B; An M; Wang L; Ding H; Zhang M; Han X
BMC Infect Dis; 2020 Feb; 20(1):123. PubMed ID: 32046664
[TBL] [Abstract][Full Text] [Related]
6. Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.
Delviks-Frankenberry KA; Lengruber RB; Santos AF; Silveira JM; Soares MA; Kearney MF; Maldarelli F; Pathak VK
Virology; 2013 Jan; 435(2):433-41. PubMed ID: 23068886
[TBL] [Abstract][Full Text] [Related]
7. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
[TBL] [Abstract][Full Text] [Related]
8. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
[TBL] [Abstract][Full Text] [Related]
9. Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.
Gupta S; Vingerhoets J; Fransen S; Tambuyzer L; Azijn H; Frantzell A; Paredes R; Coakley E; Nijs S; Clotet B; Petropoulos CJ; Schapiro J; Huang W; Picchio G
Antimicrob Agents Chemother; 2011 Jun; 55(6):2872-9. PubMed ID: 21464253
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
11. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
[TBL] [Abstract][Full Text] [Related]
12. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
Paredes R; Puertas MC; Bannister W; Kisic M; Cozzi-Lepri A; Pou C; Bellido R; Betancor G; Bogner J; Gargalianos P; Bánhegyi D; Clotet B; Lundgren J; Menéndez-Arias L; Martinez-Picado J;
J Infect Dis; 2011 Sep; 204(5):741-52. PubMed ID: 21844300
[TBL] [Abstract][Full Text] [Related]
13. Resistance-associated mutations after initial antiretroviral treatment failure in a large cohort of patients infected with HIV-1 subtype CRF01_AE.
Praparattanapan J; Kotarathitithum W; Chaiwarith R; Nuntachit N; Sirisanthana T; Supparatpinyo K
Curr HIV Res; 2012 Dec; 10(8):647-52. PubMed ID: 23061604
[TBL] [Abstract][Full Text] [Related]
14. A simian-human immunodeficiency virus carrying the rt gene from Chinese CRF01_AE strain of HIV is sensitive to nucleoside reverse transcriptase inhibitors and has a highly genetic stability in vivo.
Wang W; Yao N; Ju B; Dong Z; Cong Z; Jiang H; Qin C; Wei Q
Microbes Infect; 2014 Jun; 16(6):461-71. PubMed ID: 24709063
[TBL] [Abstract][Full Text] [Related]
15. Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine.
Delviks-Frankenberry KA; Nikolenko GN; Maldarelli F; Hase S; Takebe Y; Pathak VK
J Virol; 2009 Sep; 83(17):8502-13. PubMed ID: 19553318
[TBL] [Abstract][Full Text] [Related]
16. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
[TBL] [Abstract][Full Text] [Related]
17. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
[TBL] [Abstract][Full Text] [Related]
18. Improvement of the oligonucleotide ligation assay for detection of the M184V drug-resistant mutation in patients infected with human immunodeficiency virus type 1 subtype CRF01_AE.
Dokuta S; Utaipat U; Praparattanapan J; Keitkarn J; Maneekarn N; Sirisanthana T; Supparatpinyo K
J Virol Methods; 2013 Jun; 190(1-2):20-8. PubMed ID: 23562659
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
Menéndez-Arias L; Betancor G; Matamoros T
Antiviral Res; 2011 Nov; 92(2):139-49. PubMed ID: 21896288
[TBL] [Abstract][Full Text] [Related]
20. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
Hachiya A; Kodama EN; Sarafianos SG; Schuckmann MM; Sakagami Y; Matsuoka M; Takiguchi M; Gatanaga H; Oka S
J Virol; 2008 Apr; 82(7):3261-70. PubMed ID: 18216099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
